Asbestos-related illnesses such as mesothelioma and asbestosis have been known to develop over a period of decades, affecting people years and years since their last exposure. Many studies over the years have suggested that the length of the amount of time that has passed since initial exposure and subsequent symptoms can increase the risk of
Archive for the 'Full Archive' Category
All articles belong to this group.
A Phase I study for cediranib, a VEGFR/PDGFR kinase inhibitor, showed promising results in shrinking tumor size and increasing survival rates for those suffering from malignant pleural mesothelioma. This is not the first time cediranib has been studied as a possible treatment for mesothelioma. In 2011/2012 a Phase II trial for cediranib conducted by researchers
Mesothelioma is a rare and aggressive cancer that is difficult to diagnose because symptoms often mimic other diseases such as pulmonary fibrosis or lung cancer. Pathology reports and biopsies help distinguish this cancer from other illnesses, but often patients will have already developed more serious symptoms because the cancer has spread by the time it
A recent study published in the British Journal of Cancer compared survival rates of mesothelioma patients that received their diagnosis through either cytological or by histological method for those with the epithelioid, biphasic, or sarcomatoid subtype of mesothelioma. The concern is that those with the biphasic subtype of mesothelioma are under diagnosed when epithelioid mesothelioma
A Phase I clinical trial for an immunotherapy treatment for malignant pleural mesothelioma and non-small cell lung cancer (NSCLC) is currently underway at the University of Pennsylvania in Philadelphia. Immunotherapy treatments support the body’s immune system response to diseases. It is often looked to as a positive alternative for treating malignancies such as mesothelioma because
A biopharmaceutical company named Aduro Biotech recently announced its collaboration with Merck to further evaluate the findings for the Phase II trial of KEYTRUDA ® (pembrolizumab) and to combine their own immunotherapy treatment, CRS-207. Information regarding KEYRUDA ® treatment began to circulate late last year when data presented at the 17th World Conference on Lung
The results of a 2016 Phase III trial of the monoclonal antibody bevacizumab (Avastin) have established another option for treatment for those suffering from malignant pleural mesothelioma. Angiogenesis, which is the formation of new blood vessels, plays a key role in mesothelioma because it allows the tumors and cancer to spread. However, scientists and researchers
While surgical techniques are not the most common effort when it comes to treating mesothelioma, the pleurectomy/decortication (P/D) is a technique that has been the most successful over the years. A recent study took a look at the different surgical techniques that can be used with P/D and noted the overall effects on the patient.
The latest success concerning a treatment for non- small cell lung cancer (NSCLC) has scientists and researchers hopeful that the same treatment can be applied to mesothelioma victims. The Phase III trial for Alecensa (alectinib), while currently not recruiting participants, is on-going and results thus far have shown to be promising for those with NSCLC.
Although still in the preliminary stages, scientists and researchers are excited to announce recent research involving a treatment that is used for certain types of multiple sclerosis (MS) and its effects on combating mesothelioma. This therapeutic agent is called Immune System Modulator FTY720 (fingolimod) and is interestingly derived from a certain type of fungus called
The latest findings in cancer treatments for the often fatal mesothelioma have scientists and researchers hopeful that they are one step closer in finding a consistent, effective treatment for the asbestos-caused cancer. The LUME-Meso Phase II trial for patients with malignant pleural mesothelioma focused on the administration of the triple angiokinase inhibitor called Nintedanib. This oral
On March 29, 2017 the U.S. Senate passed S. Res.98; a resolution designating the first week of April as “National Asbestos Awareness Week” in an attempt to warn and educate the public about asbestos exposure and its deadly health effects. Despite it being a known carcinogen and its ban in many countries, it is not
Asbestosis, while not a cancerous condition, is serious and potentially life-threatening chronic disease that is caused by breathing in asbestos fibers. A person who has been diagnosed with asbestosis has a much higher chance of developing lung cancer or pleural mesothelioma, a fatal cancer affecting the lining of the lungs. While not all asbestosis cases
A new bill was approved by the U.S. House Judiciary Committee that could damage the asbestos claims process and prevent victims of asbestos-related diseases from ever seeing any sort of monetary compensation before they pass. The legislation is “H.R. 906” and is referred to as the “Furthering Asbestos Claims Transparency Act.” If this bill is
The overall nutritional health of a patient suffering from mesothelioma can have major impact on how the patient will respond to treatment, which affects patient survival. To determine a patient’s nutritional factors on a more exact basis, researchers and scientists from Japan used a scoring system called Controlling Nutritional Status score, or CONUT. CONUT scores
Last update: March 06, 2014. 08:41:31 pm.